These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 37133522)

  • 21. A multi-sequence and habitat-based MRI radiomics signature for preoperative prediction of MGMT promoter methylation in astrocytomas with prognostic implication.
    Wei J; Yang G; Hao X; Gu D; Tan Y; Wang X; Dong D; Zhang S; Wang L; Zhang H; Tian J
    Eur Radiol; 2019 Feb; 29(2):877-888. PubMed ID: 30039219
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Primary mismatch repair deficient IDH-mutant astrocytoma (PMMRDIA) is a distinct type with a poor prognosis.
    Suwala AK; Stichel D; Schrimpf D; Kloor M; Wefers AK; Reinhardt A; Maas SLN; Kratz CP; Schweizer L; Hasselblatt M; Snuderl M; Abedalthagafi MSJ; Abdullaev Z; Monoranu CM; Bergmann M; Pekrun A; Freyschlag C; Aronica E; Kramm CM; Hinz F; Sievers P; Korshunov A; Kool M; Pfister SM; Sturm D; Jones DTW; Wick W; Unterberg A; Hartmann C; Dodgshun A; Tabori U; Wesseling P; Sahm F; von Deimling A; Reuss DE
    Acta Neuropathol; 2021 Jan; 141(1):85-100. PubMed ID: 33216206
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Multi-pool chemical exchange saturation transfer MRI in glioma grading, molecular subtyping and evaluating tumor proliferation.
    Zhu H; Li Y; Ding Y; Liu Y; Shen N; Xie Y; Yan S; Liu D; Zhang X; Li L; Zhu W
    J Neurooncol; 2024 Sep; 169(2):287-297. PubMed ID: 38874844
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ultra-high-field sodium MRI as biomarker for tumor extent, grade and IDH mutation status in glioma patients.
    Regnery S; Behl NGR; Platt T; Weinfurtner N; Windisch P; Deike-Hofmann K; Sahm F; Bendszus M; Debus J; Ladd ME; Schlemmer HP; Rieken S; Adeberg S; Paech D
    Neuroimage Clin; 2020; 28():102427. PubMed ID: 33002860
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Magnetic resonance imaging criteria for prediction of isocitrate dehydrogenase (IDH) mutation status in patients with grade II-III astrocytoma and oligodendroglioma.
    Çelik S; Öven BB; Demir MK; Yılmaz EÇ; Kanan D; Özdamarlar U; Emirzeoglu L; Yapıcıer Ö; Kılıç T
    Clin Neurol Neurosurg; 2021 Aug; 207():106745. PubMed ID: 34146841
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The association between
    Okita Y; Shofuda T; Kanematsu D; Yoshioka E; Kodama Y; Mano M; Kinoshita M; Nonaka M; Fujinaka T; Kanemura Y
    Clin Radiol; 2020 Aug; 75(8):622-628. PubMed ID: 32321646
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Low expression of Ki-67/MIB-1 labeling index in IDH wild type glioblastoma predicts prolonged survival independently by MGMT methylation status.
    Tini P; Yavoroska M; Mazzei MA; Miracco C; Pirtoli L; Tomaciello M; Marampon F; Minniti G
    J Neurooncol; 2023 Jun; 163(2):339-344. PubMed ID: 37227648
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Radio-chemotherapy improves survival in IDH-mutant, 1p/19q non-codeleted secondary high-grade astrocytoma patients.
    Juratli TA; Lautenschläger T; Geiger KD; Pinzer T; Krause M; Schackert G; Krex D
    J Neurooncol; 2015 Sep; 124(2):197-205. PubMed ID: 26033545
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Radiomics-based prediction of multiple gene alteration incorporating mutual genetic information in glioblastoma and grade 4 astrocytoma, IDH-mutant.
    Sohn B; An C; Kim D; Ahn SS; Han K; Kim SH; Kang SG; Chang JH; Lee SK
    J Neurooncol; 2021 Dec; 155(3):267-276. PubMed ID: 34648115
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Predictive value of MGMT promoter methylation on the survival of TMZ treated
    Chai R; Li G; Liu Y; Zhang K; Zhao Z; Wu F; Chang Y; Pang B; Li J; Li Y; Jiang T; Wang Y
    Cancer Biol Med; 2021 Feb; 18(1):272-282. PubMed ID: 33628600
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Relationship between tumor enhancement, edema, IDH1 mutational status, MGMT promoter methylation, and survival in glioblastoma.
    Carrillo JA; Lai A; Nghiemphu PL; Kim HJ; Phillips HS; Kharbanda S; Moftakhar P; Lalaezari S; Yong W; Ellingson BM; Cloughesy TF; Pope WB
    AJNR Am J Neuroradiol; 2012 Aug; 33(7):1349-55. PubMed ID: 22322613
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical Neuropathology practice news 2-2014: ATRX, a new candidate biomarker in gliomas.
    Haberler C; Wöhrer A
    Clin Neuropathol; 2014; 33(2):108-11. PubMed ID: 24559763
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Monocentric evaluation of Ki-67 labeling index in combination with a modified RPA score as a prognostic factor for survival in IDH-wildtype glioblastoma patients treated with radiochemotherapy.
    Dumke R; Dumke C; Eberle F; Nimsky C; Keber U; Engenhart-Cabillic R; Lautenschläger S
    Strahlenther Onkol; 2022 Oct; 198(10):892-906. PubMed ID: 35612598
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Multicenter clinical radiomics-integrated model based on [
    Zhang L; Pan H; Liu Z; Gao J; Xu X; Wang L; Wang J; Tang Y; Cao X; Kan Y; Wen Z; Chen J; Huang D; Chen S; Li Y
    Eur Radiol; 2023 Feb; 33(2):872-883. PubMed ID: 35984514
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Diffusion- and perfusion-weighted MRI radiomics model may predict isocitrate dehydrogenase (IDH) mutation and tumor aggressiveness in diffuse lower grade glioma.
    Kim M; Jung SY; Park JE; Jo Y; Park SY; Nam SJ; Kim JH; Kim HS
    Eur Radiol; 2020 Apr; 30(4):2142-2151. PubMed ID: 31828414
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Use of telomerase promoter mutations to mark specific molecular subsets with reciprocal clinical behavior in IDH mutant and IDH wild-type diffuse gliomas.
    Akyerli CB; Yüksel Ş; Can Ö; Erson-Omay EZ; Oktay Y; Coşgun E; Ülgen E; Erdemgil Y; Sav A; von Deimling A; Günel M; Yakıcıer MC; Pamir MN; Özduman K
    J Neurosurg; 2018 Apr; 128(4):1102-1114. PubMed ID: 28621624
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of Radiomics Analyses Based on Different Magnetic Resonance Imaging Sequences in Grading and Molecular Genomic Typing of Glioma.
    Huang WY; Wen LH; Wu G; Hu MZ; Zhang CC; Chen F; Zhao JN
    J Comput Assist Tomogr; 2021 Jan-Feb 01; 45(1):110-120. PubMed ID: 33475317
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Relationship between molecular characteristics of glioblastoma multiforme and the subventricular zone.
    Ashraf M; Abdelsadg M; Grivas A
    Br J Neurosurg; 2024 Oct; 38(5):1100-1107. PubMed ID: 35038937
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Low MGMT digital expression is associated with a better outcome of IDH1 wildtype glioblastomas treated with temozolomide.
    Gomes I; Moreno DA; Dos Reis MB; da Silva LS; Leal LF; Gonçalves GM; Pereira CA; Oliveira MA; de Medeiros Matsushita M; Reis RM
    J Neurooncol; 2021 Jan; 151(2):135-144. PubMed ID: 33400009
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Noninvasively evaluating the grade and IDH mutation status of gliomas by using mono-exponential, bi-exponential diffusion-weighted imaging and three-dimensional pseudo-continuous arterial spin labeling.
    Guo D; Jiang B
    Eur J Radiol; 2023 Mar; 160():110721. PubMed ID: 36738600
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.